Robert D. McBane, II, M.D.

Closed for Enrollment

• A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

  This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism.

• A Phase IV, Randomized, Double Blind Study Evaluating the Safety and Efficacy of Apixaban in Subjects with Calf Vein Thrombosis La Crosse, Wis., Eau Claire, Wis., Rochester, Minn.

  The purpose of this study is to determine whether prescribing apixaban (Eliquis®) is more effective in treating and preventing pulmonary embolisms and subsequent DVTs than monitoring the calf DVT with ultrasound imaging alone.

• Efficacy and Safety of Early Exercise Program After Acute DVT for Prevention of Post Thrombotic Syndrome – Pilot Study Rochester, Minn.

  The pupose of this study is to determine the effect of exercise on patients with an acute deep vein thrombosis.

• Efficacy of direct oral anticoagulants (Rivaroxabn and Apixaban) in treatment of malignancy associated venous thromboembolism (VTE). Rochester, Minn.

  To evaluate the efficacy of rivaroxaban and apixaban in treating malignancy associated VTE by comparing to the standard of care, low molecular weight heparin (LMWH) and compare safety profile (bleeding diathesis) of rivaroxaban and apixaban in patients with malignancy associated VTE and compare it to LMWH treatment.

   

• Intermittent Pneumatic Compression Device Assessment in Patients with Severe Arterial and Venous Disease of the Lower Extremity Rochester, Minn.

  The purpose of this study is to determine whether a specific external compression pump called the AVT pump can improve blood flow to the skin of the feet in patients with circulatory problems involving the arteries or veins of the legs. The use of the AVT pump in this study is considered investigational, which means it has either not been approved by the Food and Drug Administration (FDA) for routine clinical use or for the use described in this study.

• Natural History of Segmental Arterial Mediolysis Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.

  The purpose of this study is to review the medical records of patients with  previous diagnosis of segmental arterial mediolysis or fibromuscular dysplasia to determine and compare risk factors, patient demographics, rates of recurrence, and survival.

• Thoracic Outlet Syndrome Registry Rochester, Minn.

  The overall aim of this approach to develop a patient-centric best-practice approach to the evaluation and treatment of patients with thoracic outlet syndrome (TOS).